¤é´Á

ºtÁ¿ªÌ

ÃD¥Ø

¯Á®Ñ¸¹

92/01/01

¤å¬ü­ëÂå®v

µÇŦ²¾´Ó¤§¯f²z

V9201

92/01/10

´^­P¤¤Âå®v                                ¦ó¤WªåÂå®v                            ªL©¨¥ÁÂå®v

¥þ°|Á{§É¯f²z®×¨Ò°Q½×·|

V9202

92/01/17

­ðªÃ½÷Âå®v

·s¥@¬ö¥Íª«¸ê°T¤Î¦¨ªGµoªí

V9203

92/02/21

«À¤åÁn¥D¥ô

¨xŦ²¾´Óªº³Â¾K

V9204

92/01/24

ªô«n­^Âå®v

¼~Æ{¯gÃĪ«ªvÀøªºÁͶÕ

V9205

92/02/21

¨H§Ó¶§¦Ñ®v

¨ÅÀù¤À¤l¾÷Âà¬ã¨s

V9206

92/02/28

¤ý°ê·Ó±Ð±Â

The Pathogenesis and Prevention of Steroid Induced Osteonecrosis

V9207

92/03/07

ù±RªN¥D¥ô

¹ü°ò¥~¶Ë¤¤¤ß²Ä¤@¦~¦^ÅU»P®i±æ

V9208

92/03/21

À¹·|ÀsÂå®v                           ³¯«T¦NÂå®v                           ¶À°ê°aÂå®v

¹ü¤Æ°ò·þ±ÐÂå°|¾ÇÄ֨ൣ§¿§É¬ã¨s³ø§i

V9209

92/04/18

¥ì·J¤åÂå®v

°|¤º«æ¶E­«¯g®ð¹D°V½m¤§¹L¥h»P¥¼¨Ó

V9210

92/04/25

½²«T©ú±Ð±Â

Chemtherapy Option for Non-Small Cell Lung Cancer-An Update

V9211

92/08/01

³¯¶©§Ó±Ð±Â

¥[¤JÁp¦X°êº[¥xÆW¥¼¨Ó

V9212

92/08/08

¶À«ØÄÁÂå®v

Therapectic Roles of ACEIs/ARBs in Renal Paraenchymal Hypertension

V9213

92/08/22

´¿­õ©ú±Ð±Â

DHEA:¤@ºØ¶¯©Ê²üº¸»XªºÁ{§É·N¸q

V9214

92/08/29

¤ýÄ_¥Ð±Ð±Â

ÀWÃЦ¡¦h¦â®Ö§Î¤ÀªR(SKY)¤§Á{§ÉÀ³¥Î

V9215

92/09/19

Carlos M. Forraio Ph.D.

The promise of losartan in cavdiovascular disease a vurrent pevs pective

V9216

92/09/26

´öÂ׸ÛÂå®v

Occupational health of chromium plating workers

V9217

92/10/03

David Norman Sharpe

Translation of clinical Trial Evidence into Practice:Specific lssues and Barriers to Treatment

V9218

92/10/31

³¯§ÓÂEÂå®v

Evolving Concepts in the Management of Chronic Heart Failure

V9219

92/11/07

¤ý§®´D³Õ¤h

±q°ò¦Âå¾Ç¨ìÁ{§É¤WªºÀ³¥Î:Treatment of SMA

V9220

92/11/14

ù±R³Ç¥D¥ô

Systemic inflammatory response following trauma and surgery:from bench to bedside

V9221

92/12/05

³¯ºaºÖÂå®v

New Uista of Osteoporosis Treatment A Clinical update of Evista and Forteo

V9222

92/12/12

ªL·ç²»°Æ°|ªø

·L¶q¥Õ³J¥Õ§¿Microalbuminuria

V9223

92/12/26

§õ´f¤¯Âå®v

Advance imaging diagnosis for Brain tumors

V9224

93/01/16

ªL­õ¶¯Âå®v

¥xÆWÂå®v¹ï¥xÆW¤å¤Æªº°^Äm

V9301

93/02/06

¼B«C¤s°Æ¥D¥ô

Methleneterahydrofolate Reductase °ò¦]¦h«¬©Ê

V9302

93/02/13

¼BÀé§»¡B§d¦Ü¦æÂå®v

Âå°|¸gÀç´î­«¸gÅç½Í

V9303

93/02/27

¿½¬üµ^ §Ú°ê¦b°ê»Úªº³B¹Ò V9304

93/03/05

§õ½å¶¯¬ã¨s­û The CYP21 in congenital adrenal hyperlasia V9305
 93/03/12 ¬x¦¨§ÓÂå®v ±ßµo«¬¿ò¶Ç¯e¯fªº¶EÂ_»P¿Ô¸ß V9306
93/03/19 ³³ªü­Û¥D¥ô ¥þ°ê«~½è«ü¼Ð¡]TQIP¡BTHIS¡^¢w¹ü°ò¦¨ªG³ø§i V9307
93/03/26 §õ´f¤¯Âå®v CNS infection: update- V9308
93/04/09 ¨H»ÊÃè±Ð±Â §Ü¾®¦å»s¾¯¤§¨Ï¥Î V9309
93/04/16 Pierre Amarenco, M.D. Sratins Stroke Prevention: after ASCOT positive resulrs. Hope for SPARCL V9310
93/04/23 Á§³Õ¤¯Âå®v Infection pneumoncoccus disease in Taiwan¡]ªþÁ¿¸q¡^ V9311
93/04/30 ¹ù´Â±]±Ð±Â The Role of Diuretics in Hypertension Treatment V9312
93/05/07 ¬x«a¤©¥D¥ô Cardio-renal protection V9313
93/05/14 ¨H»ÊÃè±Ð±Â Venous Thrombophilia in Taiwan V9314
93/05/28 ³¯©vÃs°Æ°|ªø This is other kind of it, Hope you'll enjoy it too !!- The Losartan Intervention For Endpoint Reduction in Hypertension Study V9315
93/06/11 ³¢¾ð¥Á±Ð±Â Current trends in congenital heart surgery V9315
93/06/18 ¥ÕªG¯à³Õ¤h Promises and challenges to the emerging biochip technologies V9316
93/07/09 «J®¶®õÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9317
93/07/16 Á¬F­õ³Õ¤h The Molecular Basis of Glycogen Storage Disease Type la: Structure and Function Analysis of Mutations in Glucose- 6- Phosphatase V9318
93/07/23 Tom Linson, P.D. Primary and Secondary Prevention of Stroke..Advantages of Ramipril - Dased Therapy V9319
93/07/30 ¨H»ÊÃè±Ð±Â New advances in disseminated intravascular coagulation¡]´²¼½©Ê¦åºÞ¤º¾®¦å¯gªº·s¶i®i¡^ V9320
93/08/06 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9321
93/08/20 ¤ý¤ô²`±Ð±Â  Treatment of peripheral arterial occllusive disease V9322
93/08/27 ´å¯à«TÂå®v Optimize insulin therapy V9323
93/09/10 ³¯¹F¤H±Ð±Â ±q¨Å©Ð¶W­µªi½Í¬ã¨sÂI¤lªº²£¥Í V9324
93/09/17 ¦¿ºÖ¥Ð±Ð±Â The Evolution of RAS Blockade- High-Risk Hypertension Management along the Cardiovascular Continuum V9325
93/09/24 ³¯ºaºÖ¥D¥ô New frontier management in Diabetic Nephropathy V9326
93/10/01 ³¯«Û¦tÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9327
93/10/08 ©P±Ò¤å¥D¥ô Æ`¤º°Ê¯ß½F¯}µõ±wªÌ¦å¼ßºû¥Í¯ÀC¡Bºû¥Í¯ÀE¯×½è¹L®ñ¤Æ¤ÏÀ³¤§ÅÜ¤ÆÆ[¹î V9328
93/10/15 §õ¦t©zÂå®v ¡uºÎ¯v¯Ê·l»P²M¿ô°IºÜ¡v(Sleep Insufficiency and Impaired Alertness) V9329
93/10/22 Professor of Medicine Mt Sinai School of Medicine New York Medicine Sol Epstein MD Treatment of Osteoporosis: A comprehensive review from a bone strengh perspective fetal therapy hydrops fetalis and oligohydramnios V9330
93/10/29 ªL­õ¨k±Ð±Â Anorectal Malformations V9331
93/11/05 ¤ý¦Ë½åÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9332
93/11/12 M. London A Global Approach to Hypertension its Cardiovascular Complication-Gerard V9333
93/11/19 ¶À®õµM³Õ¤h ³Ì·sBiomarker¤§¬ã¨s»Pµo®i V9334
93/11/26 ³¯©úÂå®v Invasive fetal therapy hydrops fetalis and oligohydramnios V9335
93/12/03 §dµOÖHÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9336
93/12/10 §ù«ä¼wÂå®v Metabolic Syndrome V9337
93/12/17 Á§³Õ¤¯Âå®v °|¤ºMRSA·P¬V V9338
93/12/24 ³¯©y§gÂå®v «Iŧ©ÊÅðµß·P¬VªvÀø·sª¾ V9339
93/12/31 ®]®a´ÉÂå®v ¦º¤`µý©ú®Ñªº¶}¨ã V9340
93/12/18 ³\­l©ú³Õ¤h ¯S§OºtÁ¿Comparison of two decoy therapeutics for BAFF, a B cell activating factor belonging to the TNF family. V9341
94/01/14 ¦DºÖ¬hÂå®v ¨xŦ¯f²z¦b¨xŦ²¾´Óªº¨¤¦â V9401
94/01/28 ®]®a´ÉÂå®v ¥Õ¦â¥¨¶ðªº±Òµo¢wÂåÀøªÈ¯É­±­±Æ[ V9402
94/02/04 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9403
94/02/18 ªL·ç²»±Ð±Â Initiation and Usage of Insulin·sªºªø®Ä¯Ø®q¯ÀGlargine V9404
94/02/19 ³¯¼[¤¯²Õªø 94¦~Âå°|Á`ÃB¹wºâºÞ²z V9405
94/02/25 ³¯©÷¥­°Æ±Ð±Â °ò¦]§ÜÅé»P¦å²M³J¥Õ¤ÀÂ÷ªºÀ³¥Î V9406
94/03/04 ªL§Ó¦¨½Òªøµ¥ ¨È¤ÓÂå¾Ç½×¾Â³Ì·sµo®iªñªp¢w2004¦~FERCAP¦~·|ªð°|³ø§i V9407
94/03/11 ¤è²`¼Ý±Ð±Â ¹L±Ó©Ê»óª¢¶EÂ_»PªvÀø V9408
94/03/18 ¤ý¥þ¥¿Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9409
94/03/22 Michael Beez Pathophysiology, monitoring and therapy of shock with organ failure V9410
94/03/25 ³¯§ÓÂE°|ªø Preventing Strategies for Vascular Disease-targeting endothelial dysfunction V9411
94/04/01 ³¯¬L¨}Âå®v Non-Invasive Advanced Airway Management V9412
94/04/08 ¬_¦¨°ê±Ð±Â ¬ã¨s¤Î±Ð¾ÇªºÂå°|¤å¤Æ V9413
94/04/15 ¿ÛÂE»·§U²z±Ð±Â ¤À¤l¼Ð¹v®ÖºØªvÀø¨ÒÃÒ¡G¶u¸K¦@¸üÅé´C¤¶©ñ¸KªvÀø©ó¤À¤Æ¥Òª¬¸¢Àù¤§À³¥Î V9414
94/04/29 ´¿¦p²WÂå®v °ª¦åÀ£¤§¤£¯à©¿²¤ªºªvÀø¥Ø¼Ð¢w­°§C²M±á¦åÀ£ÆJ¤É V9415
94/05/06 ³¯¬v·½Âå®v Âù®ðÅn¤p¸zÃèÀˬd V9416
94/05/13 §ù«ä¼wÂå®v ¿}§¿¯f»P¶gÃä¦åºÞ¯e¯f¶EÂ_»P³B²z V9417
94/05/27 ½²¥@¿AÂå®v ¿}§¿¯fÃĪ«ªvÀøªº·sÁÍ¶Õ V9418
94/06/03 ¤_®¶ªFÂå®v Management of Knee Joint Osteoarthritis V9419
94/06/10 ³¯§g¨Ô±Ð±Â Corneal Epithelial Stem Cell and Its Clinical Application V9420
94/06/17 ·¨¯ª¥ú¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9421
94/06/24 Prof. Philip Barter New Challenge, New Standard, New Satin V9422
94/07/01 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9423
94/07/08 ®]®a´ÉÂå®v §ä¦^«æ¶E«Çªº¬K¤Ñ V9424
94/07/15 Á®a©úÂå®v ¥¿¤l¹q¸£Â_¼h¡]PET/CT¡^¤§Á{§ÉÀ³¥Î V9425
94/07/22 ¼B«C¤s¥D¥ô 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢wmitochondrial disease V9426
94/07/29 ³¯¦Û½ÌÂå®v Application of Laparoscopy in Colon and Rectal Cancer Surgery V9427
94/08/05 Á©ӾëÂå®v ¹ï°ªÀ£®ñªvÀøªº»{ÃÑ V9428
94/08/12 Dr. Michael L. Leski ­^¤å½×¤å¼g§@ V9429
94/08/19 ¤ý°êºÕ±Ð±Â ©`¦Ì¥ÍÂå V9430
94/08/26 Socrates E Papapoubs Pro Developm ent in Bisphosphonate Therapy in Osteoporosis Facts, Questions and Fiction V9431
94/09/02 ù¼z¬Ã³Õ¤h¡F§d«H§»Âå®v 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w1.¥H°Êª«¹êÅç¤Î¤HÅé¸ÕÅç¶i¦æÀç¾i¬ÛÃö¬ã¨s¤§¸gÅç¤À¨É¡F2.Á{§ÉÂå®v»P°ò¦¬ã¨s V9432
94/09/16 ¶À³Ó½åÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9433
94/09/23 ªL²M²W°|ªø 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w¥ÀÅé°ª¦å¿}¹ï­L¨àµÇŦµo¨|ªº¼vÅT V9434
94/09/30 ¬_¤å­õ±Ð±Â ¥~¬ì³N«á·ÓÅ@¡]Post-op care in severe IA¡^ V9435
94/10/07 ·Å¥Ã¹|Âå®v ºÎ¯vÂå¾Çªº·sµo®i V9436
94/10/14 ªL­õ¨kÂå®v ·Rªº¦A³y½Í°_ V9437
94/10/21 §õ´f¤¯Âå®v Low Back Pain V9438
94/10/28 ­S¬u¤sÂå®v¡F·¨¤O¿ÅÂå®v ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9439
94/11/04 ¤ý¤h©¾Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9440
94/11/11 ³¯¾_¾È±Ð±Â Assessment of Ventriculo-arterial Coupling by Automated Systolic Time Intervals V9441
94/11/18 ªL¥@ÅMÂå®v Continuous Glucose Monitoring System V9442
94/11/25 Prof. Wolfgang. Eisert Antithrombotic treatment of the vessel wall?--rather than antiplatelet or anticoagulant therapy V9443
94/12/02 ÃQÄ£´§±Ð±Â 1.¦p¦ó¼¶¼g½×¤å¤Î¬ã¨s­pµe¡F2.¦p¦ó¥Ó½Ð°ê®a«¬­pµe V9444
94/12/09 prof. Ronald F. Grossman Initial management of Patient with Community-acquired Pneumo V9445
94/12/16 ªL©¯¹D°Æ®Õªø ¨ÅÀù³N«á¥ß§Y¨Å©Ð­««Ø V9446
94/12/23 ¨H©úÃè±Ð±Â¡FĬ­õ«T¥D¥ô 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w1.A.¥xÆWÃþ¦å¤Í¯fªº¬ã¨s¢wªì³ø¡AB.¹ü°ò°©Åè¼W´Þ¯gªº¬ã¨s¡F2.»{Ãѹü¤Æ¢w¤fµÄÀùÆ[ÂI¡C V9447
94/12/30 ®]®a´ÉÂå®v «æ¶E«Ç¤º¹ï¥æ³q¨Æ¬Gªº»{ª¾ V9448
95/01/06 ³¯©úÂå®v 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢wExplore the Frontier of Fetal Medicine and Clinical Genetics:from risky novel clinical therapy to benchwork94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢wExplore the Frontier of Fetal Medicine and Clinical Genetics:from risky novel clinical therapy to benchwork V9501
95/01/13 Joseph A. Paladino Professor Major Treatment guideline of hospital -- acquired Pneumonia-- an Overview and Outlook V9502
95/01/20 ¿½´I·½Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9503
95/02/03 ³\¤W¤HÂå®v ¯f¾ú¼g§@ V9504
95/02/10 ´¿©À¥ÍÂå®v Palliative medicine treatment of depression in the medically ill V9505
95/02/17 ³¯¨j¦{±Ð±Â ·F²Ó­M¬ã¨sªº°g«ä»P¼ç¤O V9506
95/02/24 ³¯ºaºÖ¥D¥ô New Vista of Osteoporsis Treatment V9507
95/03/03 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9508
95/03/10 Melody H. Lin Human Subjects Protections in Clinical ResearchRoles & Responsibilities V9509
95/03/17 Dr. Han-Mou Tsai Recent Advances in the Diagnosis and Treatment of TTP V9510
95/03/24 ¦¿±á®¦±Ð±Â Beta-Blocker¦b¤ß°IºÜªºªvÀø V9511
95/03/31 ³¯«T¦NÂå®v¡F±i¶iÄ_¥D¥ôµ¥ ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9512
95/04/07 §ù«ä¼w°|ªø The rational use of prandial glucose regulator in hospital V9513
95/04/11 ¶À¸Î´Ü±Ð±Â Update on the Management of Sepsis: An Evidence-Based Approach -- ±Ñ¦å¯gªvÀø¤§³Ì·s¹êÃÒ V9514
95/04/14 Á¬F­õ³Õ¤h 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w¤HÃþ¸²µå¿}¤§ÁC»Ä酶b¥½ºÝµ²ºc¹ï¨ä³J¥Õí©w©Ê¤ÎÁC»Ä¤ô¸Ñ¬¡©Ê¤§¼vÅT V9515
95/04/21 ±i¥¿¶¯°Æ°|ªø ¦p¦ó§iª¾­t­±ªº®ø®§ V9516
95/04/28 ¤ý°ê·Ó®Õªø Effects of Anti-inflammatory Drugs on Osteogenic Cells V9517
95/05/05 ³\·ç©÷Âå®v¡F·¨¯\­µÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9518
95/05/12 ªL§»¹F±Ð±Â Fasping or Postprandial Glycemia, What  Matters Most ? V9519
95/05/19 ¤ý°ê¶§¥D¥ô Pharmacotherapy in Atherothermbosis V9520
95/05/26 ¥ÕªG¯à³Õ¤h Circulating tumor cell detection and its applications in lung cancer studies(ªÍÀù²Ó­M¦b¦å²G´`Àô¤¤ªº°»´ú¤Î¨äÁ{§ÉÀ³¥Î) V9521
95/06/02 §ÅÁíÀM¥D¥ô Surgical treatment in parkinson,s disease V9522
95/06/09 Áé´¼²W¥D¥ô Introduction of blood component therapy V9523
95/06/16 ·Å¤¯©MÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9524
95/06/23 ªL¦P´ËÂå®v 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C-AN ASSOCIATION OF DNMT3b PROTEIN EXPRESSION WITH P16INK4a PROMOTER HYPERMETHYLATION IN NON-SMOKING FEMALE LUNG CANCER WITH HUMAN PAPILLOMAVIRUS INFECTION¤Î±qÁ{§É¨ì°ò¦¬ã¨s¤§¤ß¸ô¾úµ{ V9525
95/06/30 ¸­§»¤@Âå®v Cardiovascular Protective Effects¡GThe Role of ARBs V9526
95/07/07 ¼B«C¤s¥D¥ô ¿ò¶Ç­Û²z:±q»RÁЯg»P¤p¸£µäÁY¯g½Í°_ V9527
95/07/21 §õªFª¢Âå®v¡F³¯³ó«WÂå¥D¥ô ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q V9528
95/07/28 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9529
95/08/04 »¯¹Å­ÛÂå®v The Role of AntiPlatelte in Athorothrombosis V9530
95/08/11 ³¯ºaºÖ¥D¥ô Oxidant stress & Diabetes complication V9531
95/08/18 ·¨¤O¿Å°|ªø ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9532
95/08/25 ­S¸t¿³°Æ±Ð±Â ¥HªGÃǬã¨s¤HÃþªº¯e¯f¡A¥i¯à¶Ü¡H V9533
95/09/01 §õ§B¼ý±Ð±Â ¦¨¤jÂå°|±À°Ê¾¹®½Á~¶Ç¥Í©Rªº²z©À»P§@ªk V9534
95/09/08 ³\¤W¤HÂå®v ¯f¾ú¼g§@ V9535
95/09/15 James Kuang- Jan Liao Prof. Are All Statins The Same ? V9536
95/09/22 William L. Nyhan, Ph.D.    Maple Syrup Urine disease/Liver Transplant V9537
95/09/29 ±iÑÔº³Âå®v¡F³¢¾ð¥Á±Ð±Â ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q V9538
95/10/13 ªL¥@ÅMÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9539
95/10/20 Á«ä¥ÁÂå®v Management of Hospital-acquired Pneumonia and the Role of Fluoroquinolones V9540
95/10/27 Toronto General Hospital Peter P. Liu Halting the Progression from Post-MI to Heart Failure. V9541
95/11/03 ±i«Ø°ê°Æ°|ªø Modulating the alternative splicing of exon 7 of SMN gene by drugs. V9542
95/11/10 ±ç¤å±Ó°Æ±Ð±Â °ÝÃD¾É¦Vªº²Î­p¤ÀªR V9543
95/11/17 ³\´f«í±Ð±Â Insulin reseielance oxidative stree and cardiovasculor disease V9544
95/11/24 À¹¼zÀsÂå®vµ¥ ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q V9545
95/12/01 ¾G´J¤¯Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9546
95/12/08 Pro.Marc De Broe New insight into the mechanism of nephrolithesis. V9547
95/12/15 ©PªQ¨k±Ð±Â Vaccine Against Cervical Cancer: A Breakthrough in 21st Century¡]¤G¤Q¤@¥@¬öÂå¾Ç¤j¬ð¯}¡G¹ï§Ü¤l®cÀVÀùªº¬Ì­]µo©ú¡^ V9548
95/12/22 ³¯¥þ¤ì±Ð±Â DNA¥Ò°ò¤Æ°ò¦]´¹¤ù¤§¬ãµo¤Î¨äÀ³¥Î©ó¸ÑºcÀù¯g¤§¡§¤W¿ò¶Ç©Ê¡¨Åܲ§ V9549
95/12/29 ¥Û©ú·×°Æ°|ªø History of Artificial Airways V9550
96/01/05 ¿½©sªÚ±Ð±Â ½E¬Ì¾y¼v V9601
96/01/12 ±iª÷°í±Ð±Â ¦]À³°ª¬ì§ÞÂåÀø¤§·s­Û²zÆ[ V9602
96/01/19 ¬x°·²MÂå®v µg¯eªü¦Ì¤Ú­ì¦ä·P¬V»P·R´þ¯f¬r·P¬V V9603
96/02/02 ±iª÷°í±Ð±Â ¦åºÞ·s¥Í»PÀù¯g V9604
96/02/09 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9605
96/03/02 ùºúÁ¾¥D¥ô ¨D¤¤¤§Âå V9606
96/03/09 Pro. Paul Richard Conlin The benefical effects of mono and combination AllA thrapy to lower blood pressure for diabetes patients V9607
96/03/16 Pro. Andrew M. Tonkin Lipids-who, why and how to treat? Targets are important V9608
96/03/23 ªL¥È«ßÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9609
96/03/30 ³¯¨qº³±Ð±Â ¨ÅÀù¦h­«°»´ú¤èªk»P¯e¯f¦ÛµM¥v V9610
96/04/06 ªLºû¬wÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9611
96/04/13 ³¯ºaºÖ¥D¥ô Statin- The Role Between the Kidney & Heart V9612
96/04/20 ·¨­§Âå®v ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q V9613
96/04/27 ¿à౹ťD¥ô Medical Teaching through PBL+EBM V9615
96/05/11 ³¯°ö­õ°|¤h Major Liver Diseases in Taiwan: From Hepatitis B to Others. V9616
96/05/18 ªô¬±ªÚÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9617
96/05/25 «J©ú¾W±Ð±Â ¨ÅÀù¥~¬ìªvÀøªº¹L¥h¡B²{¦b¡B¥¼¨Ó V9618
96/06/01 §õ¥ú¥ÓÂå®v Mesenchymal Stem Cells: An Update V9619
96/06/08 ³¯©úÂå®v ¿ò¶Ç¾Ç¬ã¨s¤èªkºî¡GÁ{§ÉÂå®v¦p¦ó»P¿ò¶Ç¾Ç®a·¾³q V9620
96/06/15 ·¨´¼¥þÂå®v ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q V9621
96/06/22 §d©ú¾§¥D¥ô Management of CKD V9622
96/06/29 Á©ú®a¥D¥ô The risk factors for corony artery disease and nephropathy in Chinese with type 2 diabetes V9623
96/07/06 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9624
96/07/13 ªL¥Ã­õ±Ð±Â ¦Ñ®v±Ð»£ V9625
96/07/20 §õ¤ë§g±Ð±Â Analyzing genomic alterations in human glioma cells by molecular cytogenetics V9626
96/08/03 ¤ý¥þ¥¿Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9628
96/08/10 §ù«ä¼w°|ªø ¨È¬w²Ä2«¬¿}§¿¯f¨Ö¦³©PÃä°Ê¯ß¯e¯fªº²±¦æ²v»PÁ{§Éªí¼x¤§¦h°ê¬ã¨s V9629
96/08/17 ³¯ÂE¾_±Ð±Â ¦p¦óÁ×§K¤£·íªº¼Æ¾Ú³B²z¡]How to avoid inappropriate data processing¡^ V9630
96/08/24 §d¦Ü¦æÂå®v Awareness and Knowledge of Osteoporosis in Taiwan V9631
96/08/31 ³¯³ó«W¥D¥ô Liver transplantation in CCH V9632
96/09/07 Szilard Voros MD. The Role of Lipoproteins Atherogenesis V9633
96/09/14 §õ½÷±Ð±Â Environmental Exposure and Lung Cancer V9634
96/09/21 Dr. Bjorn Dahlof JIKEI Heart Study: How can we improve outcome in Asian patients? V9635
96/09/28 §ÅÁíÀM¥D¥ô ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9636
96/10/05 ¾G¶®¤å°Æ±Ð±Â Human Papillomavirus 16/18 E6 Oncoprotein is Expressed in Lung Cancer and Related with P53 Inactivation V9637
96/10/26 ½²¹FªQ¥D¥ô °ª¦MÀI¯f±wÀR¯ß®ê¶ë¤§³Ì¨Î¹w¨¾ V9640
96/11/02 ¬I¿o»ÊÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9641
96/11/09 ·¨¤å¥ú±Ð±Â ´c©Ê¸£½F¤§¾ð¬ð²Ó­M¸~½F¬Ì­]ªvÀø¡GÁ{§É¸ÕÅç»P¨ä«á¤§ÂàĶÂå¾Ç¬ã¨s V9642
96/11/16 ³\ªÃ¹ç©Òªø Role of chemokine receptor CCR6 in induction of gastric inflammation during Helicobacter infection V9643
96/11/23 ³¯©÷©úÂå®v Better stroke prevention : The role of ARBs V9644
96/11/30 ¾G§¡¬§Âå®v ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9645
96/12/07 ¦¿±á®¦±Ð±Â ¦å¯×ªvÀø·s²z©À V9646
96/12/14 PhD James Shepherd Safe and effective treatment for diabetic dyslipidaemia V9647
96/12/21 ³¯Ãý¤§Âå®v ºÎ¯v©I§l¤¤¤î¯g V9648
96/12/28 ¸­§»¤@°Æ¥D¥ô Lipid Management 2007--Where do we stand? V9649
97/01/04 ¶À¥ü¤s¥D¥ô ¦~«×©ÊÀR¯ßª`®gÂùÁC»ÄÆQ¦b°©ÃPªvÀø¤Wªº·s¶i®i V9700
97/01/11 ½²¬F¾Ë¸³¨Æªø ·F²Ó­M¬ãµo V9701
97/01/18 ªL¤¤¥Í±Ð±Â ¤ß°IºÜªvÀø--¤µ©õÆ[©Àªº®t²§ V9702
97/02/01 ³¯«Tºa°Æ°|ªø ±q¤¤­·¨¾ªv¨ì¾ã¦X©Êªº·ÓÅ@¨t²Î V9704
97/02/15 ªL·ç²»±Ð±Â ¿}§¿¯f·sª¾¢w1.ATP±Ó·P©Ê¹[Â÷¤l³q¹D¤Î·s¥Í¨à¿}§¿¯f¡F2.GIP, GLI-1»PExenatide V9705
97/02/22 ³\¤W¤HÂå®v 97¦~²Ä¤@³õ¡u¯f¾ú¼g§@±Ð¾Ç¡v¬ã²ß·| V9706
97/02/29 ¶À±i±ù§g±Ð±Â Utility of oligonucleotide array-base comparative genomic hybridization for detection of intragenic deletions V9707
97/03/07 ªL´Ü¶í±Ð±Â Nasopharyngeal carcinoma: molecular pathogenesis, gene expression profiling and clinical intervention V9708
97/03/14 Prof. Rick Adachi Bone Formation Agent for Severe Osteoporosis Management V9709
97/03/28 ªô§Ó¤åÂå®v ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9711
97/04/11 ªL­õ¨k±Ð±Â «÷¹Ï¤H-¨xŦ²¾´Ó¥ýÅX ¥v¹Fµ¦Âå¥Í¶Ç°O V9712
97/04/18 §õÌɾËÂå®v Current surgical treatment for morbid obesity V9713
97/04/25 ±i¤¤©M¬ã¨s­û ging,reactive oxygenoxygen species and advancedglycation end products(ages) V9714
97/05/02 ½²«C¶§¥D¥ô ¨­Åé»P¤ßÆFªº¸Ñ­å V9715
97/05/09 ªô¼ü©úÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9716
97/05/16 ¦¿±á®¦±Ð±Â Treatment of hypertension: where do we stand in 2008? V9717
97/05/30 ³¯¾å¯àÂå®v ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9719
97/06/06 ¤ý´_¼w¥D¥ô ­²Äõ¤ó¶§©Êµß·P¬VªºªvÀø V9720
97/06/13 ©P¤ÖµØÂå®v ÂåÀø±¡¹Ò¤¤¨â©ÊÃö«Y V9721
97/06/20 ¬I¹Å©M±Ð±Â Maturation and virion release of human hepatits b virus variants V9722
97/06/27 ®]®a´É±Ð±Â ·í¹J¨ìÂåÀøªÈ¯É®É Âå°|¦p¦ó³B¸m V9723
97/07/04 ªL©¯ºa¥D¥ô ¤ßŦ°IºÜªº³Ì·sªvÀø V9724
97/07/18 §º¥Ã»í°Æ°|ªø Update management of osteporosis V9726
97/07/25 ®]³¹­ðÂå®v ÃEÃC­±·î«¬¤Î¾¦¦C«r¦X¤£¥¿¤§ªvÀø V9727
97/08/01 ªL§µ¸qÁ{§É±Ð±Â ­·Àã¯f¶EÂ_¤ÎªvÀøªºÂÕ«ä V9728
97/08/08 ³¯³s¥ÍÂå®v §U²£³Nmidwiferyªº¾ú¥v V9729
97/08/15 ³¯¹F¤H±Ð±Â 96¦~«×¬ã¨s¦¨ªG³ø§i¨t¦C¡]¤@¡^Àù¯gÂå¾Ç¬ã¨s«Ç¦~«×¦¨ªG³ø§i°ò¦¬ã¨s¨ìÁ{§É¹w¨¾Âå¾ÇÀ³¥Î V9730
97/08/20 ³\¤W¤HÂå®v 97¦~²Ä2³õ ¯f¾ú¼g§@±Ð¾Ç ¬ã²ß·| V9731
97/09/05 ½²¬F§»Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9733
97/09/26 ªLªFÀé¥D¥ô Leukocyte-depleted component therapy¡]´î°£¥Õ¦å²y«~¤§À³¥Î¡^ V9735
97/10/17 ¤ý¤h©¾Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9737
97/10/24 Lansberg, Peter Jan Vascular imaging for evaluating CHD risk and treatment assessment V9738
97/10/31 ³¯ºaºÖ¥D¥ô "Bone appetit" foundation of bone health V9739
97/11/07 §d¤ìºaÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·|¢wÂåÀøªÈ¯É¤§¯f²z¾÷Âà¡]The pathogenesis of medical malpractice¡^ V9740
97/11/14 Ĭ¥Ú¥ßÂå®v¡F©P¤ÖµØÂå®v 96¦~«×¬ã¨s¦¨ªG³ø§i¨t¦C¡]¤T¡^¡G(1)Mitochondrial DNA 16189t to c variant in patients with type 2 diabetes combined peripheral arterial disease¡F
(2)²É½uÅé¥\¯à»Ùê»Pºë¯«¯e¯f
V9741
97/11/21 ½²ÂE¼w¥D¥ô 96¦~«×¬ã¨s¦¨ªG³ø§i¨t¦C¡]¥|¡^¡G¥Í´ÞÂå¾Ç¬ã¨s«Ç¬ã¨s¦¨ªG¤¶²Ð V9742
98/01/02 ©P¦¼¤t¸³¨Æªø ½Í¾i¥Í V9800
98/01/09 §ù«ä¼w°|ªø ¥NÁ¯g­Ô¸s¤Î¿}§¿¯f±wªÌ¦å¯×²§±`ªvÀø¤§·s¥D±i V9801
98/01/16 ´¿±Ò·ç°|ªø Á{§ÉÂå®v¦p¦ó±q¨ÆÂàͬã¨s¡]How to apply trans lational research in clinical medicine¡^ V9802
98/01/23 ªL·U³¨Âå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9803
98/01/30 ¿ú«Ø¤åÂå®v ÂåÀø»P¡§©Ê§O¥D¬y¤Æ¡¨ V9804
98/02/06 ¼B«C¤s°Æ°|ªøµ¥ (ACGME)¦í°|Âå®v¤»¤j®Ö¤ß¯à¤O±Ð¾Ç V9805
98/02/13 ¤ý´_¼w¥D¥ô Âå¾Ç¤H¤å¡A­Û²zªk«ß¡A¥þ¤HÂåÀø¨â©ÊijÃD»P·P±± V9806
98/02/20 ³¢³Õ¬L±Ð±Â ¥Í²z«ß°Ê¤ÀªR¨t²Î¤§¬ãµoÀ³¥Î¤Î¥¼¨Ó®i±æ V9807
98/03/06 §d¤ìºaÂå®v ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·|¢wÂåÀøªÈ¯É»PªkÂå¸Ñ­å V9809
98/03/13 ¶À«T¶¯Âå®v 2009¦~²Ä¤@³õ¡u¯f¾ú¼g§@±Ð¾Ç¡v V9810
98/03/20 Lawrence A. Leiter Professor Inflammation in Atherosclerosis Is it clinically important? Results of recent clinical trials V9811
98/03/27 ±i§»°ò¥D¥ô ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9812
98/03/27 ¦¿¦Û±o¥D¥ô ¸Ö¡BÂå¾Ç¡B¥xÆW V9813
98/04/03 ¼B«C¤s°Æ°|ªø ¦åºÞº[°ò¦]Åé¬ã¨s¤¤¤ß2009¦~¦¨ªGµoªí·| V9814
98/04/17 Asprer Jonathan Pro. Immunomodulation by nutrition therapy surgery and critical illness. V9816
98/04/24 ¬I´º¤¤Âå®v Placenta accreta in the 21th century the new horizon with 3D power doppler and temporally balloon occlusion of CIA V9817
98/05/01 Kenneth A. Jamerson M.D. Hypertension control in high risk patients V9818
98/05/08 ¬I­ZªL ±qªk«ß·sµø¬É½Í¥Í©R»PÂåÀøªk«ß V9819
98/05/29 ³¯ºaºÖ¥D¥ô °©ÃPªvÀøªº·s¶i®i V9822
98/06/05 ¶À¤ô©[±Ð±Â The Development of radiofrequency catheter ablation of cardiac arrhythmias implication for becoming a physician seientist V9824
98/06/12 §õ¤¸ÄQ¥D¥ô §Úªº¥~¬ì¥Í²P»PªÍŦ²¾´Ó V9825
98/06/19 §dÂE©úÂå®v Bridging bench to clinic: roles of glia for the therapy of neurologic diseases V9826
98/06/26 ·¨§Ó°¶Âå®v ÂåÀø¹Î¶¤¦X§@°V½m V9827
98/07/03 ³\¥Ã²»¥D¥ô ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| V9828
98/07/10 ¬x¦¨§Ó±Ð±Â ¦­µo«¬¥¢´¼¯gªº°ò¦]¶EÂ_»P¿ò¶Ç¿Ô¸ß V9829
98/07/17 ½²¦æ¿«°Æ°|ªø °ê¤º¤Î°ê»ÚªÅ¤¤ºò«æÂåÀø±Ï´© V9830
98/07/24 ³\´fùÚ¥D¥ô Linking Metabolic Momory and CV disease: What have we learned? V9831
98/07/31 ¶À«T¶¯¥D¥ô ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q V9832
98/08/14 ¸­«Û§B§½ªø Âå°|¬°°ò¦ªº°·±dºÞ²zµ¦²¤ V9834
98/08/21 ¤ý¤h©¾Âå®v ¿é¦åÂå¾Ç V9835

§ó·s¤é´Á:2009/11/04